A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Neuropsychopharmacology

• Publication date

  2010-06-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/npp.2010.79PMID 20555312PMCID PMC3055301
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

  2010cited by this paper
• Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

  2010cited by this paper
• Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

  2009cited by this paper
• Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia

  2009cited by this paper
• Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.

  2008cited by this paper
• Switching to Long-Acting Injectable Risperidone is Beneficial with Regard to Clinical Outcomes, Regardless of Previous Conventional Medication in Patients with Schizophrenia

  2007cited by this paper
• Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study

  2007cited by this paper
• Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia.

  2007cited by this paper
• A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia

  2007cited by this paper
• Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.

  2007cited by this paper
• The case for long‐acting antipsychotic agents in the post‐CATIE era

  2007cited by this paper
• Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.

  2007cited by this paper
• Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

  2007cited by this paper
• Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic

  2006cited by this paper
• Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.

  2006cited by this paper
• Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

  2006cited by this paper
• The expert consensus guideline series. Treatment of behavioral emergencies 2005.

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.

  2004cited by this paper
• Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.

  2004cited by this paper
• Safety and Tolerability: How Do Newer Generation “Atypical” Antipsychotics Compare?

  2004cited by this paper
• Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.

  2004cited by this paper
• Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.

  2003cited by this paper
• Antipsychotics and QT prolongation

  2003cited by this paper
• Partial compliance and patient consequences in schizophrenia: our patients can do better.

  2003cited by this paper
• The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

  2003cited by this paper
• Optimizing pharmacologic treatment of psychotic disorders

  2003cited by this paper
• Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome

  2002cited by this paper
• Strategies for increasing treatment compliance: the role of long-acting antipsychotics.

  2002cited by this paper
• The Expert Consensus Guideline Series: Treatment of Epilepsy

  2001cited by this paper
• Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning

  2000cited by this paper
• A Rating Scale for Drug-Induced Akathisia

  1989cited by this paper
• A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

  1970cited by this paper

• Quality by Design in parenteral drug development: Addressing formulation challenges and industrial insights.

  2026cites this paper
• Comparison of Side Effects Between 3‐Monthly and 1‐Monthly Paliperidone Palmitate Formulations in Patients With Schizophrenia

  2026cites this paper
• Paliperidone Palmitate Toxicity in Chronic Kidney Disease: A Case of Life-Threatening Autonomic Failure

  2025influential citation
• Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia

  2025cites this paper
• GAMT Deficiency: Clinical Presentation, Treatment, Diagnosis, Animal Models, Preclinical and Clinical Developments

  2025cites this paper
• Investigation on the factors associated with maintenance of paliperidone long-acting injection in the real-world treatment of patients with schizophrenia

  2025cites this paper
• Antipsychotic Acute-Phase Treatment in Individuals With and Without Recent Treatment: An Individual Participant Data Meta-Analysis.

  2025cites this paper
• Choosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide

  2025cites this paper
• Plasma Protein Patterns Associated with Paliperidone Palmitate Maintenance Therapy in Schizophrenia: A Prospective Cohort Study

  2025cites this paper
• The development of paliperidone nanocrystals for the treatment of schizophrenia

  2024cites this paper
• The effect of second-generation antipsychotics on anxiety/depression in patients with schizophrenia: A systematic review and meta-analysis.

  2024cites this paper
• ANTIPSYCHOTIC DRUGS: THREE GENERATIONS OF ANTIPSYCHOTICS

  2024cites this paper
• Pharmacological and Somatic Treatment Effects on Suicide in Adults: A Systematic Review and Meta-Analysis.

  2023cites this paper
• Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety

  2023cites this paper
• Comparative Safety of Long-Acting Injectable Antipsychotics: A Systematic Review and Network Meta-Analysis

  2023cites this paper
• A randomized, prospective, active-controlled study comparing intramuscular long-acting paliperidone palmitate versus oral antipsychotics in patients with schizophrenia at risk of violent behavior.

  2023cites this paper
• Calibrated meta-analysis to estimate the efficacy of mental health treatments in target populations: an application to paliperidone trials for treatment of schizophrenia

  2023cites this paper
• Computational Prodrug Design Methodology for Liposome Formulability Enhancement of Small-Molecule APIs

  2023cites this paper
• Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents

  2022cites this paper
• Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis

  2022cites this paper
• [Second-generation long-acting injectable antipsychotics in clinical practice].

  2022cites this paper
• The association of metabolic syndrome and long acting injectable antipsychotics: A systematic review

  2022cites this paper
• Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.

  2022cites this paper
• The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly

  2021cites this paper
• Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate

  2021cites this paper
• Pharmacological and somatic treatment effects on suicide in adults: A systematic review and meta‐analysis

  2021cites this paper
• NDT_A_309768 1917..1926

  2021cites this paper
• Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia

  2021cites this paper
• Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN)

  2021cites this paper
• Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports

  2021cites this paper
• Long-acting injectable antipsychotics: what, when, and how

  2021cites this paper
• Impact of Formulation Parameters on In Vitro Release from Long-Acting Injectable Suspensions

  2021cites this paper
• Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials

  2021cites this paper
• Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate

  2021cites this paper
• Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile

  2021cites this paper
• Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea

  2020cites this paper
• Development of acute hepatotoxicity following the first dose of paliperidone palmitate: a case report

  2020cites this paper
• Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis

  2020cites this paper
• Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis.

  2020cites this paper
• Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis.

  2020cites this paper
• Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.

  2019cites this paper
• Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia: A Real-World Multicenter, Retrospective, Mirror-Image Study.

  2019cites this paper
• The impact of the ambiguous definition of "month" on pharmacotherapy.

  2019cites this paper
• Hospitalizations and economic analysis in psychotic patients with paliperidone palmitate long-acting injection

  2019cites this paper
• Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

  2019cites this paper
• Systematic Review of Gender Bias in the Clinical Trials of New Long-Acting Antipsychotic Drugs

  2019cites this paper
• Analyzing Nanotheraputics Based Approaches For The Management Of Psychotic Disorders.

  2019cites this paper
• Paliperidone palmitate in short- and long-term treatment of schizophrenia.

  2019cites this paper
• Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

  2019cites this paper
• Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.

  2018cites this paper
• Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life

  2018cites this paper
• Risk of weight gain for specific antipsychotic drugs: a meta-analysis

  2018cites this paper
• The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia

  2018cites this paper
• Анализ длительной терапии препаратом Ксеплион больных шизофренией

  2018cites this paper
• Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

  2018cites this paper
• Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics

  2018cites this paper
• head-to-head comparison of 1-year aripiprazole long-acting injectable (lai) versus paliperidone lai in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life

  2018cites this paper
• Safety concerns associated with second-generation antipsychotic long-acting injection treatment. A systematic update

  2018cites this paper
• Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia

  2018cites this paper
• The Isoxazole Ring and Its N‐Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics

  2017cites this paper
• Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety

  2017cites this paper
• Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.

  2017cites this paper
• Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method.

  2017cites this paper
• Suicide Prevention in Schizophrenia: Do Long-Acting Injectable Antipsychotics (LAIs) have a Role?

  2017cites this paper
• Paliperidone Long-Acting Plasma Level Monitoring and a New Method of Evaluation of Clinical Stability

  2017cites this paper
• Effectiveness of paliperidone depot injection in seriously violent men with comorbid schizophrenia and dissocial personality disorder in a UK high-security hospital

  2017cites this paper
• Validation of the Five-Factor Model of the Arabic Version of the Positive and Negative Syndrome Scale in Schizophrenia

  2017cites this paper
• Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.

  2017cites this paper
• Hospitalizations and economic analysis in psychotic patients with paliperidone palmitate long-acting injection ☆

  2017cites this paper
• Hospitalizations and economic analysis in psychotic patients with paliperidone palmitate long-acting injection.

  2017cites this paper
• Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation

  2017cites this paper
• Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison

  2017influential citation
• Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia

  2016cites this paper
• Genome-wide association study of paliperidone efficacy

  2016cites this paper
• Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal

  2016cites this paper
• Paliperidone Palmitate-induced Urinary Incontinence: A Case Report

  2016cites this paper
• Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

  2016cites this paper
• Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life

  2016cites this paper
• The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.

  2016cites this paper
• Paliperidone Palmitate Treatment in Outpatient Care Setting: A Naturalistic Study.

  2016cites this paper
• Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland

  2016cites this paper
• Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: A phase‐1, single‐dose, randomized, open‐label study

  2016cites this paper
• Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia

  2016cites this paper
• Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia

  2016cites this paper
• The Use of Long-Acting Injectable Antipsychotics in Schizophrenia : Evaluating the Evidence Part 1 : Efficacy and Safety of LAIs � � �

  2016cites this paper
• Three-month paliperidone palmitate - a new treatment option for schizophrenia

  2016cites this paper
• Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia

  2015cites this paper
• Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.

  2015cites this paper
• Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.

  2015influential citation
• Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review

  2015cites this paper
• Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study

  2015cites this paper
• Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia

  2015cites this paper
• Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study

  2015cites this paper
• Weight gain and antipsychotics: a drug safety review

  2015cites this paper
• Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia

  2015cites this paper
• Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia

  2015cites this paper
• Eficacia de palmitato de paliperidona, suspensión inyectable de liberación prolongada, en pacientes con patología dual

  2015cites this paper
• Barrier-mediated pulsatile release

  2015cites this paper
• Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

  2015cites this paper
• Додаток 2 План проведення наукових конференцій та семінарів з проблем вищої освіти і науки у Тернопільському національному технічному університеті імені Івана Пулюя на 2014р

  2014cites this paper